Patents by Inventor Pernilla Sandberg

Pernilla Sandberg has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Non-anilinic derivatives of isothiazol-3(2H)-one 1,1-dioxides as liver X receptor modulators
    Patent number: 7960380
    Abstract: The present invention relates to certain novel compounds of the formula (I) to processes for preparing such compounds, to their the utility in modulation of nuclear hormone receptors Liver X Receptor (LXR) ? (NR1H3) and/or ? (NR1H2) and in treating and/or preventing clinical conditions including cardiovascular diseases such as atherosclerosis; inflammatory diseases, Alzheimer's disease, lipid disorders (dyslipidemias) whether or not associated with insulin resistance, type 2 diabetes and other manifestations of the metabolic syndrome, to methods for their therapeutic use and to pharmaceutical compositions containing them.
    Type: Grant
    Filed: March 17, 2010
    Date of Patent: June 14, 2011
    Assignee: AstraZeneca AB
    Inventors: Anders Broo, Robert Judkins, Lanna Li, Eva-Lotte Lindstedt-Alstermark, Pernilla Sandberg, Marianne Swanson, Lars Weidolf, Kay Brickmann, Patrik Holm
  • Non-Anilinic Derivatives Of Isothiazol-3(2H)-one 1,1-Dioxides As Liver X Receptor Modulators
    Publication number: 20100227847
    Abstract: The present invention relates to certain novel compounds of the formula (I) to processes for preparing such compounds, to their the utility in modulation of nuclear hormone receptors Liver X Receptor (LXR) ? (NR1H3) and/or ? (NR1H2) and in treating and/or preventing clinical conditions including cardiovascular diseases such as atherosclerosis; inflammatory diseases, Alzheimer's disease, lipid disorders (dyslipidemias) whether or not associated with insulin resistance, type 2 diabetes and other manifestations of the metabolic syndrome, to methods for their therapeutic use and to pharmaceutical compositions containing them.
    Type: Application
    Filed: March 17, 2010
    Publication date: September 9, 2010
    Applicant: ASTRAZENECA AB
    Inventors: Anders Broo, Robert Judkins, Lanna Li, Eva-Lotte Lindstedt-Alstermark, Pernilla Sandberg, Marianne Swanson, Lars Weidolf, Kay Brickmann, Patrik Holm
  • Non-anilinic derivatives of isothiazol-3(2H)-one 1,1-dioxides as liver X receptor modulators
    Patent number: 7723333
    Abstract: The present invention relates to certain novel compounds of the formula (I) to processes for preparing such compounds, to their the utility in modulation of nuclear hormone receptors Liver X Receptor (LXR) ? (NR1H3) and/or ? (NR1H2) and in treating and/or preventing clinical conditions including cardiovascular diseases such as atherosclerosis; inflammatory diseases, Alzheimer's disease, lipid disorders (dyslipidemias) whether or not associated with insulin resistance, type 2 diabetes and other manifestations of the metabolic syndrome, to methods for their therapeutic use and to pharmaceutical compositions containing them.
    Type: Grant
    Filed: January 9, 2006
    Date of Patent: May 25, 2010
    Assignee: AstraZeneca AB
    Inventors: Anders Broo, Robert Judkins, Lanna Li, Eva-Lotte Lindstedt-Alstermark, Pernilla Sandberg, Marianne Swanson, Lars Weidolf, Kay Brickmann, Patrik Holm
  • DERIVATIVES OF ISOTHIAZOL-3(2H)-ONE 1,1-DIOXIDES AS LIVER X RECEPTOR MODULATOR
    Publication number: 20100016321
    Abstract: The present invention relates to certain novel compounds of the formula (I) to processes for preparing such compounds, to their utility in modulation of nuclear hormone receptors Liver X Receptor (LXR) ? (NR1H3) and/or ? (NR1H2) and in treating and/or preventing clinical conditions including cardiovascular diseases such as atherosclerosis; inflammatory diseases, Alzheimer's disease, lipid disorders (dyslipidemias) whether or not associated with insulin resistance, type 2 diabetes and other manifestations of the metabolic syndrome, to methods for their therapeutic use and to pharmaceutical compositions containing them.
    Type: Application
    Filed: July 23, 2009
    Publication date: January 21, 2010
    Applicant: ASTRAZENECA AB
    Inventors: Jonas Bostrom, Kay Brickmann, Anders Broo, Robert Judkins, Lanna Li, Pernilla Sandberg, Marianne Swanson, Christer Westerlund, Patrik Holm
  • Derivatives of isothiazol-3(2)-one 1,1-dioxides as liver X receptor modulators
    Patent number: 7582629
    Abstract: The present invention relates to certain novel compounds of the formula (I) to processes for preparing such compounds, to their the utility in modulation of nuclear hormone receptors Liver X Receptor (LXR) ? (NR1H3) and/or ? (NR1H2) and in treating and/or preventing clinical conditions including cardiovascular diseases such as atherosclerosis; inflammatory diseases, Alzheimer's disease, lipid disorders (dyslipidemias) whether or not associated with insulin resistance, type 2 diabetes and other manifestations of the metabolic syndrome, to methods for their therapeutic use and to pharmaceutical compositions containing them.
    Type: Grant
    Filed: January 9, 2006
    Date of Patent: September 1, 2009
    Assignee: AstraZeneca AB
    Inventors: Jonas Boström, Kay Brickmann, Anders Broo, Robert Judkins, Lanna Li, Pernilla Sandberg, Marianne Swanson, Christer Westerlund, Patrik Holm
  • Non-Anilinic Derivatives of Isothiazol-3(2H)-one 1,1-Dioxides as Liver X Receptor Modulators
    Publication number: 20090005353
    Abstract: The present invention relates to certain novel compounds of the formula (I) to processes for preparing such compounds, to their the utility in modulation of nuclear hormone receptors Liver X Receptor (LXR) ? (NR1H3) and/or ? (NR1H2) and in treating and/or preventing clinical conditions including cardiovascular diseases such as atherosclerosis; inflammatory diseases, Alzheimer's disease, lipid disorders (dyslipidemias) whether or not associated with insulin resistance, type 2 diabetes and other manifestations of the metabolic syndrome, to methods for their therapeutic use and to pharmaceutical compositions containing them.
    Type: Application
    Filed: January 9, 2006
    Publication date: January 1, 2009
    Applicant: AstraZeneca AB
    Inventors: Anders Broo, Robert Judkins, Lanna Li, Eva-Lotte Lindstedt-Alstermark, Pernilla Sandberg, Marianne Swanson, Lars Weidolf, Kay Brickmann, Patrik Holm
  • Derivatives of Isothiazol-3(2H)-One 1,1-Dioxides as Liver X Receptor Modulators
    Publication number: 20080255122
    Abstract: The present invention relates to certain novel compounds of the formula (I) to processes for preparing such compounds, to their the utility in modulation of nuclear hormone receptors Liver X Receptor (LXR) ? (NR1H3) and/or ? (NR1H2) and in treating and/or preventing clinical conditions including cardiovascular diseases such as atherosclerosis; inflammatory diseases, Alzheimer's disease, lipid disorders (dyslipidemias) whether or not associated with insulin resistance, type 2 diabetes and other manifestations of the metabolic syndrome, to methods for their therapeutic use and to pharmaceutical compositions containing them.
    Type: Application
    Filed: January 9, 2006
    Publication date: October 16, 2008
    Applicant: ASTRAZENECA AB
    Inventors: Jonas Bostrom, Kay Brickmann, Anders Broo, Robert Judkins, Lanna Li, Pernilla Sandberg, Marianne Swanson, Christer Westerlund, Patrik Holm
  • Pyrrole-2,5-dione derivatives as Liver X receptor modulators
    Patent number: 7432288
    Abstract: The present invention relates to certain novel compounds of the Formula I to processes for preparing such compounds, to their the utility in modulation of nuclear hormone receptors Liver X Receptor (LXR)?(NR1H3) and/or ?(NR1H2) and in treating and/or preventing clinical conditions including cardiovascular diseases such as atherosclerosis; inflammatory diseases, Alzheimer's disease, lipid disorders (dyslipidemias) whether or not associated with insulin resistance, type 2 diabetes and other manifestations of the metabolic syndrome, to methods for their therapeutic use and to pharmaceutical compositions containing them.
    Type: Grant
    Filed: July 8, 2004
    Date of Patent: October 7, 2008
    Assignee: AstraZeneca AB
    Inventors: Jonas Boström, Kay Brickmann, Patrik Holm, Pernilla Sandberg, Marianne Swanson, Christer Westerlund
  • Mchir antagonists
    Publication number: 20060247439
    Abstract: The present invention provides compounds of formula (I), wherein R1 represents a C1-4 alkoxy group optionally substituted by one or more fluoro or a C1-4alkyl group optionally substituted by one or more fluoro; n represents 0 or 1; R2 represents a C1-4alkyl group optionally substituted by one or more fluoro or a C1-4alkoxy group optionally substituted by one or more fluoro; m represents 0 or 1; R3 represents H or a C1-4alkyl group; L1 represents an alkylene chain (CH2)r in which r represents 2 or 3 or L1 represents a cyclohexyl group wherein the two nitrogens bearing R3 and R4, respectively, are linked to the cyclohexyl group either via the 1,3 or the 1,4 positions of the cyclohexyl group or L1 represents a cyclopentyl group wherein the two nitrogens bearing R3 and R4, respectively, are linked to the cyclopentyl group via the 1,3 position of the cyclopentyl group and additionally when R5 represents 9,10-methanoanthracen-9(10H)-yl the group -L1-N(R4)— together represents a piperidyl ring which is linked to L2
    Type: Application
    Filed: July 4, 2003
    Publication date: November 2, 2006
    Applicant: AstraZeneca AB
    Inventors: Asim Ray, Emma Evertsson, Anna Stina Linusson Jonsson, Pernilla Sandberg, Tord Ingiiardt, Anette Svensson, Kay Brickmann